123 related articles for article (PubMed ID: 1840228)
21. Novel potent and selective central 5-HT3 receptor ligands provided with different intrinsic efficacy. 2. Molecular basis of the intrinsic efficacy of arylpiperazine derivatives at the central 5-HT3 receptors.
Cappelli A; Anzini M; Vomero S; Canullo L; Mennuni L; Makovec F; Doucet E; Hamon M; Menziani MC; De Benedetti PG; Bruni G; Romeo MR; Giorgi G; Donati A
J Med Chem; 1999 May; 42(9):1556-75. PubMed ID: 10229626
[TBL] [Abstract][Full Text] [Related]
22. Effect of FK1052, a potent 5-hydroxytryptamine3 and 5-hydroxytryptamine4 receptor dual antagonist, on colonic function in vivo.
Kadowaki M; Nagakura Y; Tomoi M; Mori J; Kohsaka M
J Pharmacol Exp Ther; 1993 Jul; 266(1):74-80. PubMed ID: 8331576
[TBL] [Abstract][Full Text] [Related]
23. The influence of 5-HT2 and 5-HT4 receptor antagonists to modify drug induced disinhibitory effects in the mouse light/dark test.
Costall B; Naylor RJ
Br J Pharmacol; 1997 Nov; 122(6):1105-18. PubMed ID: 9401775
[TBL] [Abstract][Full Text] [Related]
24. Is there a relationship between serotonin receptor subtypes and selectivity of response in specific psychiatric illnesses?
Montgomery SA; Fineberg N
Br J Psychiatry Suppl; 1989 Dec; (8):63-9. PubMed ID: 2692641
[TBL] [Abstract][Full Text] [Related]
25. Evidence for a 5-HT3 receptor involvement in the facilitation of peristalsis on mucosal application of 5-HT in the guinea pig isolated ileum.
Tuladhar BR; Kaisar M; Naylor RJ
Br J Pharmacol; 1997 Nov; 122(6):1174-8. PubMed ID: 9401783
[TBL] [Abstract][Full Text] [Related]
26. Release of endogenous dopamine by stimulation of 5-hydroxytryptamine3 receptors in rat striatum.
Blandina P; Goldfarb J; Craddock-Royal B; Green JP
J Pharmacol Exp Ther; 1989 Dec; 251(3):803-9. PubMed ID: 2600815
[TBL] [Abstract][Full Text] [Related]
27. Serotonin receptor subtypes: implications for psychopharmacology.
Cowen PJ
Br J Psychiatry Suppl; 1991 Sep; (12):7-14. PubMed ID: 1840764
[TBL] [Abstract][Full Text] [Related]
28. Effects of chronic administration of ondansetron (GR38032F), a selective 5-HT3 receptor antagonist, on monoamine metabolism in mesolimbic and nigrostriatal dopaminergic neurons and on striatal D2-receptor binding.
Koulu M; Lappalainen J; Hietala J; Sjöholm B
Psychopharmacology (Berl); 1990; 101(2):168-71. PubMed ID: 2140903
[TBL] [Abstract][Full Text] [Related]
29. The psychopharmacology of 5-HT3 receptors.
Costall B; Naylor RJ; Tyers MB
Pharmacol Ther; 1990; 47(2):181-202. PubMed ID: 2203069
[TBL] [Abstract][Full Text] [Related]
30. Effect of 5-hydroxytryptamine3 receptor agonists on phosphoinositides hydrolysis in the rat fronto-cingulate and entorhinal cortices.
Edwards E; Harkins K; Ashby CR; Wang RY
J Pharmacol Exp Ther; 1991 Mar; 256(3):1025-32. PubMed ID: 1848625
[TBL] [Abstract][Full Text] [Related]
31. 5-HT(6) receptor and cognition.
Codony X; Vela JM; Ramírez MJ
Curr Opin Pharmacol; 2011 Feb; 11(1):94-100. PubMed ID: 21330210
[TBL] [Abstract][Full Text] [Related]
32. Lack of effects of 5-HT3 antagonists on normal and morphine-attenuated sexual behaviours in female and male rats.
Tanco SA; Watson NV; Gorzalka BB
Experientia; 1993 Mar; 49(3):238-41. PubMed ID: 8458409
[TBL] [Abstract][Full Text] [Related]
33. The breadth of action of the 5-HT3 receptor antagonists.
Costall B
Int Clin Psychopharmacol; 1993 Nov; 8 Suppl 2():3-9. PubMed ID: 8201244
[TBL] [Abstract][Full Text] [Related]
34. [Serotonin (5-HT)3 receptors: antagonists and their pharmacological profiles].
Miyata K; Honda K
Nihon Yakurigaku Zasshi; 1994 Sep; 104(3):143-52. PubMed ID: 7959407
[TBL] [Abstract][Full Text] [Related]
35. Effect of the 5-HT3 receptor antagonist, GR38032F, on responses to injection of a neurokinin agonist into the ventral tegmental area of the rat brain.
Hagan RM; Butler A; Hill JM; Jordan CC; Ireland SJ; Tyers MB
Eur J Pharmacol; 1987 Jun; 138(2):303-5. PubMed ID: 2442006
[No Abstract] [Full Text] [Related]
36. Involvement of 5-HT3 receptors in the prolactin release induced by immobilization stress in rats.
Nonaka KO
Prog Neuropsychopharmacol Biol Psychiatry; 1999 Apr; 23(3):497-503. PubMed ID: 10378232
[TBL] [Abstract][Full Text] [Related]
37. Cognitive implications for H3 and 5-HT3 receptor modulation of cortical cholinergic function: a parallel story.
Passani MB; Blandina P
Methods Find Exp Clin Pharmacol; 1998 Oct; 20(8):725-33. PubMed ID: 9922988
[TBL] [Abstract][Full Text] [Related]
38. Interactions between 5-HT3 receptors and cerebral dopamine function: implications for the treatment of schizophrenia and psychoactive substance abuse.
Hagan RM; Kilpatrick GJ; Tyers MB
Psychopharmacology (Berl); 1993; 112(1 Suppl):S68-75. PubMed ID: 7831443
[TBL] [Abstract][Full Text] [Related]
39. 5-HT6 receptor ligands and their antipsychotic potential.
Arnt J; Olsen CK
Int Rev Neurobiol; 2011; 96():141-61. PubMed ID: 21329787
[No Abstract] [Full Text] [Related]
40. Anxiolytic potential of 5-HT3 receptor antagonists.
Costall B; Naylor RJ
Pharmacol Toxicol; 1992 Mar; 70(3):157-62. PubMed ID: 1349746
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
